A recreational trail runner in their early 40s returned to full training after a painful L5-S1 annular tear, using an intra-annular fibrin injection as an alternative to fusion. Pain scores tracked the published fibrin cohort — VAS fell from 72.4 mm to 33.0 mm at 104 weeks. This is an illustrative composite drawn from published outcome patterns.

Note: This case is an illustrative composite based on published clinical outcome patterns for intra-annular fibrin injection in active patients with lumbar annular tears. No identifying patient details have been used.

Case Snapshot

Why Did Conservative Care Fall Short?

Before reaching ValorSpine, this patient completed 16 weeks of structured physical therapy emphasizing lumbar stabilization, two epidural steroid injections, and an extended NSAID trial. Pain returned within weeks of each steroid injection — consistent with the AAFP systematic review that classifies epidurals as not effective for chronic low back pain alone.

A 3T lumbar MRI showed a posterior annular tear at L5-S1 with a high-intensity zone on T2 sequences, preserved disc height, and no extruded fragment. Two surgical consultations recommended microdiscectomy with annular closure or single-level L5-S1 fusion. The patient declined both. Back surgery has roughly a 40% failure rate, and a 3–6 month fusion recovery was incompatible with an active running life.

What Was the Clinical Rationale for Fibrin Treatment?

ValorSpine evaluated the patient for intra-annular fibrin injection, a biologic disc repair procedure that delivers an FDA-approved fibrin sealant directly into the annular defect. Unlike epidural steroids that target inflammation systemically, fibrin treatment provides a structural scaffold for the body to seal the tear from within.

The clinical match was strong: contained lesion, hydrated disc, lean and conditioned patient, clear imaging-symptom correlation. Published cohort data on intra-annular fibrin injection report VAS pain falling from 72.4 mm at baseline to 33.0 mm at 104 weeks, with 70% patient satisfaction at two-year follow-up. For a single-level annular tear in a surgery-naive patient, those numbers compared favorably to both fusion outcomes and the natural history of untreated tears. A clinical evaluation is the only way to know whether this approach fits an individual patient’s anatomy and history.

Expert Take

Patient selection is what drives results with fibrin-based disc treatment. A contained annular tear with preserved disc height and a clean imaging-symptom match is the indication where these procedures perform best. Loose selection criteria produce loose outcomes. Patients whose imaging shows extruded fragments, severe disc height loss, or instability are not good candidates — and pushing them through produces results that regress to the mean of conservative care.

What Did the Recovery Timeline Look Like?

The procedure was performed as an outpatient intervention under fluoroscopic guidance. Total time under 60 minutes. The patient was discharged the same day with a written rehabilitation protocol:

• Weeks 1–2: Walking only. No bending, lifting, or twisting.
• Weeks 3–6: Graded core and hip stabilization. No running. Stationary bike permitted.
• Weeks 7–12: Light jogging on flat terrain. Progressive volume.
• Weeks 13–26: Trail running on rolling terrain with moderate descents.
• Week 27 onward: Full training load with technical descents.

Compliance was strong. A transient flare in week 2 — consistent with the local biologic response phase — resolved without intervention. By week 8, the patient was running 12–15 minute intervals on flat terrain without symptom reproduction.

How Did the Outcomes Compare to Published Data?

The 104-week VAS of 33.0 mm matches the published cohort endpoint exactly. The 39.4 mm absolute reduction crosses the threshold for clinically meaningful improvement cited in spine pain research. The gain held across two years of follow-up — the native L5-S1 motion segment remained intact, avoiding the adjacent segment disease risk that follows fusion.

For a contrasting illustrative case involving a post-surgical patient, see our failed-back-surgery fibrin case study. For a veteran with a similar annular tear presentation, see the veteran annular tear fibrin case study.

What Does This Case Tell Us About Patient Selection?

• A contained annular tear with preserved disc height is the indication where fibrin-based disc treatment performs best.
• Conservative care must precede biologics — but only to the point where the trajectory is clearly established. Sixteen weeks of PT and two failed steroid injections was sufficient here.
• The post-procedure protocol matters as much as the procedure. Athletes who push the return-to-running timeline trade durable results for early mileage.
• A 39.4 mm VAS reduction held at two years — the motion segment stayed intact. Fusion revision risk was avoided entirely.

Frequently Asked Questions

How long after intra-annular fibrin injection can a recreational athlete return to running?

Most recreational athletes with isolated annular tears reintroduce light jogging on flat terrain at weeks 7–12 and full training load by month 6. The 12-week window protects annular healing. Pushing earlier mileage degrades durability. A clinical evaluation is the only way to know what timeline fits a specific patient’s anatomy and procedure response.

What VAS pain reduction does the published fibrin cohort report at two years?

Published cohort data report VAS pain falling from 72.4 mm at baseline to 33.0 mm at 104 weeks — a 39.4 mm absolute reduction that exceeds the threshold for clinically meaningful improvement. Two-year satisfaction in the same cohort runs at 70%.

Is fibrin disc treatment appropriate for every annular tear?

No. Fibrin-based disc treatment is indicated for contained annular tears in structurally intact discs, in patients who have failed conservative therapy but do not yet meet criteria for fusion. Extruded fragments, severe disc height loss, or instability shift the clinical picture toward surgical options. A clinical evaluation is the only way to determine candidacy.

Can fibrin injection work after failed back surgery?

Published series report that 80% of failed-back-surgery patients had positive outcomes with fibrin injection. Selection criteria still apply. Surgery-naive patients with isolated annular tears sit in a more favorable outcome subset than post-surgical patients. See our failed-back-surgery fibrin case study for the post-operative pathway.

Sources

• Peer-reviewed clinical literature on intra-annular fibrin injection — for the 72.4 to 33.0 mm VAS trajectory and 70% two-year satisfaction figures.
• American Academy of Family Physicians (AAFP) — systematic review classifying epidural steroid injections as not effective for chronic low back pain alone.
• Industry consensus / peer-reviewed FBSS literature — for the 40% failure rate figure cited in context of surgical alternatives.
• National Institute of Neurological Disorders and Stroke (NINDS) — background on annular tear pathology and lumbar disc anatomy.

Next Steps

If you have a lumbar annular tear and have not found lasting relief with physical therapy or injections, a clinical evaluation is the starting point. Review non-surgical alternatives to fusion or contact ValorSpine to discuss whether biologic disc repair fits your clinical picture.

This content is for general informational purposes only and does not constitute medical advice, diagnosis, or treatment. It is not a substitute for evaluation by a qualified physician. Treatment decisions depend on your individual medical history and clinical findings. Schedule a consultation to discuss whether the procedure is right for you.